October 23, 2016 6:52 PM ET


Company Overview of Conatus Pharmaceuticals Inc.

Company Overview

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase II clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response, non-alcoholic steatohepatitis, and nonalcoholic fatty liver disease and raised transaminases, as well as for the treatment of patients with severe alcoholic hepatitis. The company was founded in 2005 and is headquartered in San ...

16745 West Bernardo Drive

Suite 200

San Diego, CA 92127

United States

Founded in 2005

25 Employees



Key Executives for Conatus Pharmaceuticals Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 64
Total Annual Compensation: $473.8K
Co-Founder, Chief Scientific Officer and Executive Vice President of Research & Development
Age: 58
Total Annual Compensation: $373.6K
Co-Founder, Chief Financial Officer, Senior Vice President of Finance and Secretary
Age: 65
Total Annual Compensation: $302.6K
Executive Vice President of Clinical Development
Age: 61
Total Annual Compensation: $94.0K
Compensation as of Fiscal Year 2015.

Conatus Pharmaceuticals Inc. Key Developments

Conatus Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016

Conatus Pharmaceuticals Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2016. For the quarter, the company reported net loss of $6,471,145 or $0.30 per share basic and diluted against $6,057,254 or $0.31 per share basic and diluted a year ago. For the six months, the company reported net loss of $13,743,029 or $0.65 per share basic and diluted against $12,036,918 or $0.69 per share basic and diluted a year ago.

Conatus Pharmaceuticals Inc. to Report Q2, 2016 Results on Aug 03, 2016

Conatus Pharmaceuticals Inc. announced that they will report Q2, 2016 results After-Market on Aug 03, 2016

Conatus Pharmaceuticals Inc., Q2 2016 Earnings Call, Aug 03, 2016

Conatus Pharmaceuticals Inc., Q2 2016 Earnings Call, Aug 03, 2016

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Conatus Pharmaceuticals Inc., please visit www.conatuspharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.